• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Positive results for intranasal Ampion

Ampio Pharmaceuticals has announced results of a randomized, double-blinded study of its intranasal Ampion, a biologic anti-inflammatory, for the treatment of nasal inflammation. According to the company, Ampion “is naturally produced by humans in response to injury and is present in commercial human serum albumin (HSA) preparations.” Ampio is also developing oral and injectable forms of the drug.

The study, which was conducted at Centers for Allergy and Asthma in Denver, involved 20 patients who received either intranasal Ampion or saline and found statistically significant improvement in total nasal symptom scores for Ampion compared to placebo in moderately symptomatic patients.

Ampio Chief Regulatory Officer Vaughan Clift commented, “This trial is an important clinical milestone for the company as it is the first time that Ampion was administered as a stand-alone treatment for an inflammatory condition in humans and was well tolerated with no reported treatment related adverse events. This study expands the investigation of the anti-inflammatory mechanism of action for Ampion in our Ampion-in-Knee (AIK) trial conducted in Australia as reported on October 26, 2011. This initial AIK study required the addition of a “standard of care” steroid in each arm as it was the first use of Ampion in humans. The absence of any adverse events in the initial AIK study provided the basis for IRB approval of the present intranasal trial in the USA as well as for the direct intra-articular comparison of Ampion to steroid in an expanded osteoarthritis of the knee trial in Australia, the results of which are expected early next year.”

Clift indicated that the Ampio will use data from both trials to choose whether to pursue intranasal Ampion or another dosage form in an upcoming clinical trial in the US. According to Ampio’s website, the company also considers Ampion a potential treatment for inflammatory respiratory disease.

Read the Ampio press release.

Share

published on November 10, 2011

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews